<DOC>
	<DOCNO>NCT01680991</DOCNO>
	<brief_summary>This multi-center , open-label , single-arm study evaluate pharmacokinetics safety obinutuzumab participant cluster differentiation ( CD ) 20 positive ( + ) malignant disease . Participants receive multiple dos obinutuzumab . The anticipated time study treatment 24 week .</brief_summary>
	<brief_title>A Study Obinutuzumab Chinese Participants With CD20+ Malignant Disease</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Diagnosis CD20+ Bcell lymphoma BCLL Refractory/relapsed CLL , FL , DLBCL At least 1 measurable lesion ( great [ &gt; ] 1.5 centimeter [ cm ] large dimension ) exception CLL Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy &gt; 6 month Prior use investigational antibody therapy within 6 month study start Prior use anticancer vaccine Prior administration rituximab within 3 month study start Prior administration radioimmunotherapy 3 month prior study entry Central nervous system lymphoma History malignancy Evidence significant , uncontrolled concomitant disease Abnormal laboratory value Patients progressive multifocalleukoencephalopathy ( PML ) Infection human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>